Minerva Neurosciences (NERV) Net Income towards Common Stockholders (2013 - 2026)
Minerva Neurosciences (NERV) reported Net Income towards Common Stockholders of -$16.0 million for Q1 2026, down 328.4% on a YoY basis from $7.0 million in Q1 2025, and down 261.71% quarter-over-quarter from -$4.4 million in Q4 2025.
Minerva Neurosciences (NERV) Net Income towards Common Stockholders (2013 - 2026) Analysis & Trends
Minerva Neurosciences has reported Net Income towards Common Stockholders for 14 years, with the latest figure at -$16.0 million in Q1 2026.
- For the quarter ending Q1 2026, Net Income towards Common Stockholders fell 328.4% year-over-year to -$16.0 million; the trailing twelve-month figure through Mar 2026 stood at -$26.5 million (down 46.98% YoY), and the FY2025 full-year result was -$14.2 million, up 31.21% from the prior year.
- Net Income towards Common Stockholders for Q1 2026 stood at -$16.0 million, down from -$4.4 million in the prior quarter.
- The five-year high for Net Income towards Common Stockholders was -$2.7 million in Q3 2025, with the low at -$16.0 million in Q1 2026.
- Historically, Net Income towards Common Stockholders has averaged -$5.7 million across 5 years, with a median of -$5.0 million in 2023.
- Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders surged 77.67% — and 2026, when it tumbled 328.4%.
- Minerva Neurosciences' Net Income towards Common Stockholders stood at -$4.8 million in 2022, then slumped by 42.75% to -$6.8 million in 2023, then surged by 37.14% to -$4.3 million in 2024, then retreated by 3.56% to -$4.4 million in 2025, then tumbled by 261.71% to -$16.0 million in 2026.
- The last three Net Income towards Common Stockholders figures came in at -$16.0 million (Q1 2026), -$4.4 million (Q4 2025), and -$2.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -13.56 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 2.50 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.63 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Minerva Neurosciences | 197.55 Mn | 197.55 Mn | - | -16.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -16.04 Mn |
| Dec 31, 2025 | -4.44 Mn |
| Sep 30, 2025 | -2.74 Mn |
| Jun 30, 2025 | -3.24 Mn |
| Mar 31, 2025 | -3.74 Mn |
| Dec 31, 2024 | -4.28 Mn |
| Sep 30, 2024 | -4.05 Mn |
| Jun 30, 2024 | -5.92 Mn |
| Mar 31, 2024 | -6.32 Mn |
| Dec 31, 2023 | -6.81 Mn |
| Sep 30, 2023 | -5.73 Mn |
| Jun 30, 2023 | -4.15 Mn |
| Mar 31, 2023 | -4.98 Mn |
| Dec 31, 2022 | -4.77 Mn |
| Sep 30, 2022 | -5.03 Mn |
| Jun 30, 2022 | -6.89 Mn |
| Mar 31, 2022 | -7.98 Mn |
| Dec 31, 2021 | -21.37 Mn |
| Sep 30, 2021 | -7.51 Mn |
| Jun 30, 2021 | -8.96 Mn |